Literature DB >> 11401994

Long-term pertussis-specific immunity after primary vaccination with a combined diphtheria, tetanus, tricomponent acellular pertussis, and hepatitis B vaccine in comparison with that after natural infection.

S Esposito1, T Agliardi, A Giammanco, G Faldella, A Cascio, S Bosis, O Friscia, M Clerici, N Principi.   

Abstract

The aim of this study was to compare pertussis-specific humoral and cellular immunity in children 5 years after a primary vaccination with a combined diphtheria, tetanus, tricomponent acellular pertussis, and hepatitis B vaccine (DTaP-HBV; InfanrixHepB; SmithKline Beecham) with immunity after natural infection. The subjects were 38 children aged 5 to 6 years who received DTaP-HBV at 3, 5, and 11 months of life and 21 subjects of similar ages and sex who acquired pertussis in the first year of life. Immunoglobulin G (IgG) antibody titers against Bordetella pertussis antigens, peripheral blood mononuclear cell-specific proliferation, and the secretion of cytokines were evaluated. After 5 years, only a small proportion of vaccinated and infected children had significant specific concentrations of IgG in serum against all three B. pertussis antigens, and T-cell responses persisted in a minority of subjects. A preferential type 1 cytokine response with the secretion of gamma interferon was observed in the pertussis group, whereas a type 2 skewed response was observed in the vaccinated children; however, the quantitative differences in the cytokines produced by DTaP-HBV and natural infection were minimal. In conclusion, our results show that the immune responses induced by primary pertussis vaccination are qualitatively and quantitatively similar to those seen in children who recovered from natural infection and highlight the need for booster immunization with pertussis vaccines in order to maintain adequate levels of a specific immune response to B. pertussis.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11401994      PMCID: PMC98527          DOI: 10.1128/IAI.69.7.4516-4520.2001

Source DB:  PubMed          Journal:  Infect Immun        ISSN: 0019-9567            Impact factor:   3.441


  38 in total

1.  Cell-mediated immune response of healthy adults to Bordetella pertussis vaccine antigens.

Authors:  C M Ausiello; R Lande; A la Sala; F Urbani; A Cassone
Journal:  J Infect Dis       Date:  1998-08       Impact factor: 5.226

2.  Antibody responses and persistence in the two years after immunization with two acellular vaccines and one whole-cell vaccine against pertussis.

Authors:  M Giuliano; P Mastrantonio; A Giammanco; A Piscitelli; S Salmaso; S G Wassilak
Journal:  J Pediatr       Date:  1998-06       Impact factor: 4.406

3.  Distinct T-cell subtypes induced with whole cell and acellular pertussis vaccines in children.

Authors:  M Ryan; G Murphy; E Ryan; L Nilsson; F Shackley; L Gothefors; K Oymar; E Miller; J Storsaeter; K H Mills
Journal:  Immunology       Date:  1998-01       Impact factor: 7.397

4.  Acellular pertussis vaccines containing genetically detoxified pertussis toxin induce long-lasting humoral and cellular responses in adults.

Authors:  A Di Tommaso; M Bartalini; S Peppoloni; A Podda; R Rappuoli; M T De Magistris
Journal:  Vaccine       Date:  1997-08       Impact factor: 3.641

5.  Comparative efficacy of acellular pertussis vaccines: an analysis of recent trials.

Authors:  J D Cherry
Journal:  Pediatr Infect Dis J       Date:  1997-04       Impact factor: 2.129

6.  Randomised controlled trial of two-component, three-component, and five-component acellular pertussis vaccines compared with whole-cell pertussis vaccine. Ad Hoc Group for the Study of Pertussis Vaccines.

Authors:  P Olin; F Rasmussen; L Gustafsson; H O Hallander; H Heijbel
Journal:  Lancet       Date:  1997-11-29       Impact factor: 79.321

7.  Bordetella pertussis respiratory infection in children is associated with preferential activation of type 1 T helper cells.

Authors:  M Ryan; G Murphy; L Gothefors; L Nilsson; J Storsaeter; K H Mills
Journal:  J Infect Dis       Date:  1997-05       Impact factor: 5.226

8.  Persistence of protection through 33 months of age provided by immunization in infancy with two three-component acellular pertussis vaccines. Stage II Working Group.

Authors:  S Salmaso; P Mastrantonio; S G Wassilak; M Giuliano; A Anemona; A Giammanco; A E Tozzi; M L Ciofi degli Atti; D Greco
Journal:  Vaccine       Date:  1998-08       Impact factor: 3.641

9.  Cytokine mRNA expression and proliferative responses induced by pertussis toxin, filamentous hemagglutinin, and pertactin of Bordetella pertussis in the peripheral blood mononuclear cells of infected and immunized schoolchildren and adults.

Authors:  Q He; N N Tran Minh; K Edelman; M K Viljanen; H Arvilommi; J Mertsola
Journal:  Infect Immun       Date:  1998-08       Impact factor: 3.441

10.  A murine model in which protection correlates with pertussis vaccine efficacy in children reveals complementary roles for humoral and cell-mediated immunity in protection against Bordetella pertussis.

Authors:  K H Mills; M Ryan; E Ryan; B P Mahon
Journal:  Infect Immun       Date:  1998-02       Impact factor: 3.441

View more
  15 in total

1.  Immunological fingerprinting method for differentiation of serum samples in research-oriented biobanks.

Authors:  Katy Beaumont; Fotini Betsou
Journal:  Clin Vaccine Immunol       Date:  2010-02-17

Review 2.  Waning and aging of cellular immunity to Bordetella pertussis.

Authors:  Inonge van Twillert; Wanda G H Han; Cécile A C M van Els
Journal:  Pathog Dis       Date:  2015-09-13       Impact factor: 3.166

3.  Vaccination and the dynamics of immune evasion.

Authors:  Olivier Restif; Bryan T Grenfell
Journal:  J R Soc Interface       Date:  2007-02-22       Impact factor: 4.118

Review 4.  Prevention of pertussis: An unresolved problem.

Authors:  Susanna Esposito; Nicola Principi
Journal:  Hum Vaccin Immunother       Date:  2018-07-24       Impact factor: 3.452

5.  Effectiveness of acellular pertussis vaccination during childhood (<7 years of age) for preventing pertussis in household contacts 1-9 years old in Catalonia and Navarra (Spain).

Authors:  P Plans; D Toledo; M R Sala; N Camps; M Villanova; R Rodríguez; J Alvarez; R Solano; M García-Cenoz; I Barrabeig; P Godoy; S Minguell
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2016-09-09       Impact factor: 3.267

Review 6.  Laboratory Diagnosis of Pertussis.

Authors:  Anneke van der Zee; Joop F P Schellekens; Frits R Mooi
Journal:  Clin Microbiol Rev       Date:  2015-10       Impact factor: 26.132

Review 7.  Acellular pertussis vaccine safety and efficacy in children, adolescents and adults.

Authors:  Janet R Casey; Michael E Pichichero
Journal:  Drugs       Date:  2005       Impact factor: 9.546

8.  A live, attenuated Bordetella pertussis vaccine provides long-term protection against virulent challenge in a murine model.

Authors:  Ciaran M Skerry; Bernard P Mahon
Journal:  Clin Vaccine Immunol       Date:  2010-12-08

9.  Lessons from a mature acellular pertussis vaccination program and strategies to overcome suboptimal vaccine effectiveness.

Authors:  Ousseny Zerbo; Bruce Fireman; Nicola P Klein
Journal:  Expert Rev Vaccines       Date:  2021-10-08       Impact factor: 5.683

10.  Acellular pertussis booster in adolescents induces Th1 and memory CD8+ T cell immune response.

Authors:  Nikolaus Rieber; Anna Graf; Dominik Hartl; Simon Urschel; Bernd H Belohradsky; Johannes Liese
Journal:  PLoS One       Date:  2011-03-08       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.